Erytropoietin som mulig behandling ved hjernesygdom

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Erythropoietin (EPO) is a hypoxia-inducible hormone best known for its role in erythropoiesis. However, EPO also has anti-inflammatory and tissue-protective characteristics in multiple organs as summarised in this review. In the brain, EPO is upregulated by hypoxia, regulates ventilation and plays a key role in neuroprotection and neuroplasticity. Systemically administered EPO crosses the blood-brain-barrier, enhances neuroplasticity and improves cognitive functions in several disorders of the brain. Given this evidence, a trial is being planned to investigate whether EPO can improve the physiologic and neurologic outcome of COVID-19.

Bidragets oversatte titelErythropoietin as possible treatment of brain diseases
OriginalsprogDansk
ArtikelnummerV0420287
TidsskriftUgeskrift for Laeger
Vol/bind182
Udgave nummer44
ISSN0041-5782
StatusUdgivet - 26 okt. 2020

    Forskningsområder

  • Betacoronavirus, Brain/metabolism, Brain Diseases/drug therapy, COVID-19, Coronavirus Infections/drug therapy, Erythropoietin/therapeutic use, Humans, Pandemics, Pneumonia, Viral/drug therapy, SARS-CoV-2

ID: 256074081